+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma, 2018 - The Patient Perspective - Asia Edition

  • ID: 4969484
  • Report
  • October 2019
  • Region: Asia Pacific
  • 88 Pages
  • PatientView
1 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Eisai
  • GSK
  • Novartis
  • MORE

This the 3rd edition of 'The Corporate Reputation of Pharma - from the Perspective of Asian Patient Groups'. The 2018 results are drawn from a survey of patient groups worldwide, conducted November 2018 - February 2019.

Profile of 2018's respondent Asian patient groups:

  • 119 patient groups from 23 Asian countries, including Japan [21 patient groups]; Australia [19]; Russia [17, included in the Asia report for the first time in 2018, since three-quarters of Russia’s landmass is in Asia]; India [12]; New Zealand [10]; and other Asian countries.
  • 41 specialties (a relatively large number of the respondent Asian patient groups - 10 - specialise in a rare disease or rare diseases).
  • 3% of the respondent Asian patient groups have an international geographic remit; 55% are national patient groups; 27% are regional (within one area of their home country) and 14% are local.
  • 67% of the Asian patient groups worked with one or more pharmaceutical companies.

Company analyses: The following 23 pharma companies were analysed by the 119 Asian patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation:

AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, GSK, Janssen, Merck & Co/MSD, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche/Genentech (represented in Japan by Chugai), Sanofi, Takeda/Shire, and Teva.

Key Findings Across the Pharma Industry

Percentage of respondent Asian patient groups stating that the pharmaceutical industry has an “Excellent” or “Good” corporate reputation, 2016-2018

Since 2016, Asian patient groups have held a consistently more-positive view of the corporate reputation of the pharmaceutical industry as a whole than patient groups from many other parts of the rest of the world. Some 49% of 2018’s respondent Asian patient groups stated that the industry had an “Excellent” or “Good” corporate reputation (41% of patient groups worldwide said the same in 2018). Asian patient groups rated the pharmaceutical industry to have a higher corporate reputation in 2018 than any other healthcare sector. However, viewpoints do differ across the continent of Asia - New Zealand’s patient groups are the most positive about pharma’s corporate reputation; Japan’s are the most negative.

Similarly, Asian patient groups’ views on the pharma industry’s performance at a range of activities important to patients and patient groups vary considerably.

  • New Zealand's patient groups were generally the most positive of the Asian patient groups about the pharma industry’s ability to carry out many activities of importance to patients and patient groups. Even so (and like other patient groups worldwide), only a minority of the respondent New Zealand patient groups thought pharma “Excellent” or “Good” at being transparent - either at the transparency of pricing policies, at sharing clinical data or being transparent at the funding of external stakeholders.
  • A majority of the respondent Australian patient groups believed the pharmaceutical industry to be “Excellent” or “Good” at three activities: patient safety; innovation; and making high-quality products. Most of the Australian patient groups, however, thought the industry only “Fair” or “Poor” at other activities of importance to patients and patient groups. The comments received from the respondent Australian patient groups indicate that they consider working relationships with them to be one of the main areas in which pharmaceutical companies could improve.
  • A majority of the respondent Russian patient groups believed the pharmaceutical industry to be “Excellent” or “Good” at being innovative. However, patient groups from this country thought the industry only “Fair” or “Poor” at other activities.
  • The majority of respondent patient groups from Japan judged the pharmaceutical industry to be just “Fair” or “Poor” at all of the listed activities. Such was the case, too, among respondent patient groups from India. Patient groups in India and Japan echoed Australian patient groups in calling for more practical support from pharma.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Eisai
  • GSK
  • Novartis
  • MORE
  • Executive Summary
  • Asian Patient-Group Relationships With Pharma, 2018
  • Rankings Of 23 Pharma Companies, 2018 V. 2017 Among Asian Patient Groups Familiar With The Companies
  • Rankings Of 13 Pharma Companies, 2018 V. 2017 Among Asian Patient Groups That Work Or Partner With The Companies
  • Profiles Of The 23 Pharma Companies, 2018 V. 2017
  • Appendices
  • Appendix I: What The 119 Asian Patient Groups Say On Pharma And How The Industry Can Improve
  • Appendix II:[See Separate Report]: How The 19 Respondent Australian Patient Groups Rank 11 Pharma Companies For Corporate Reputation In Their Country, 2018

Tables and Charts

  • Percentage Of Respondent Patient Groups Stating That The Corporate Reputation Of The Pharmaceutical Industry As A Whole Was “Excellent” Or “Good”, 2016-2018 - Asian Patient Groups V. Patient Groups Worldwide
  • The Percentage Of Respondent Patient Groups Stating That The Corporate Reputation Of The Pharmaceutical Industry As A Whole Was “Excellent” Or “Good”, 2018
  • Percentage Of Respondent Asian Patient Groups Stating That The Pharmaceutical Industry As A Whole Was “Excellent” Or “Good” At Various Activities Of Importance To Patients And Patient Groups, 2018
  • The Rankings Of ‘Big Pharma’ At Corporate Reputation (Among Respondent Asian Patient Groups Familiar With The Companies), 2018
  • Respondent Asian Patient Groups: Familiarity, And Partnerships, With Pharma Companies, 2018
  • The Types Of Relationships That Respondent Asian Patient Groups Have With Pharma Companies, 2018
  • The Corporate Reputation Of The Pharmaceutical Industry, 2018 V. 2017 - Compared With Seven Other Healthcare Sectors (According To Respondent Asian Patient Groups)
  • The Corporate Reputation Of The Pharmaceutical Industry, 2016-2018, According To Respondent Asian Patient Groups
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities, According To Respondent Asian Patient Groups
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities, According To Respondent Asian Patient Groups - Compared With Previous Years
  • Rankings Of Individual Pharma Companies, 2018 V. 2017, According To Respondent Asian Patient Groups Familiar With The Company
  • Rankings Of Individual Pharma Companies, 2018 V. 2017, According To Respondent Asian Patient Groups That Work Or Partner With The Company
  • Profiles Of The 30 Companies, 2018

Charts and Tables for Each of the 23 Companies:

  • Number of respondent Asian patient groups claiming familiarity with the company, 2018.
  • Number of respondent Asian patient groups saying that they had a working relationship with the company, 2018.
  • Profile of respondent Asian patient groups familiar, and working, with the company, 2018: country headquarters; geographic location; specialties; geographic remit; and types of relationships.
  • Company scores among respondent Asian patient groups familiar with the company, and which worked or partnered with the company, for each of the 12 indicators of corporate reputation, 2018.
  • Percentage of the respondent Asian patient groups that worked or partnered with the company, but which also worked with other companies, 2018.
  • Snapshot view: where the company sits in the tiers for each of the 12 indicators of corporate reputation (in the higher, the middle, or the lower tier), as assessed by respondent Asian patient groups familiar with the company, 2018.
  • Snapshot view: where the company sits in the tiers for each of the 12 indicators of corporate reputation (in the higher, the middle, or the lower tier), as assessed by respondent Asian patient groups that work with the company, 2018.
  • The company’s Net Promoter Score (NPS).
  • The company’s overall Patient Corporate Reputation Index (PCRI), 2016-2018.
  • Overall rankings for the company, according to respondent Asian patient groups familiar with the company, 2018 v. 2017.
  • Overall rankings for the company, according to respondent Asian patient groups that work or partner with the company, 2018 v. 2017.
  • Company rankings for each of the 12 indicators, according to respondent Asian patient groups familiar, or working, with the company, 2018 v. 2017.

Company Profiles

  • Abbvie
  • Amgen
  • Astellas
  • Astrazeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Eisai
  • Eli Lilly
  • Gilead
  • GSK
  • Janssen
  • Merck & Co/Msd
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche/Genentech
  • Sanofi
  • Takeda/Shire
  • Teva  
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Eisai
  • Eli Lilly
  • Gilead
  • GSK
  • Janssen
  • Merck & Co/MSD
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche/Genentech
  • Sanofi
  • Takeda/Shire
  • Teva
Note: Product cover images may vary from those shown
Adroll
adroll